Hemodynamic and autonomic effects of intravenous saterinone in patients with chronic heart failure

Journal of Cardiovascular Pharmacology

Volumn 29, Issue 5, 1997, Pages 618-623

  Szabo B M ^a   Van Veldhuisen, D J ^a   Van Dijk, R B ^a   Lahiri, A ^b   Mitrovic, V ^c   Stolzenburg, K ^d   Brouwer, J ^a   Lie, K I ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

^c KERCKHOFF HEART CENTER   (Germany)

^d BEIERSDORF AG   (Germany)

Author keywords

Autonomic effects; Heart failure; Hemodynamic effects; Saterinone

Indexed keywords

ADRENALIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; NEUROHORMONE; NORADRENALIN; PHOSPHODIESTERASE INHIBITOR; PLACEBO; RENIN; SATERINONE;

ADULT; AGED; ARTICLE; AUTONOMIC INNERVATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; AUTONOMIC NERVOUS SYSTEM; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE, CONGESTIVE; HEART RATE; HEMODYNAMIC PROCESSES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PYRIDONES;

EID: 0031007895     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199705000-00009     Document Type: Article

References (20)

1. Packer M. The neurohumoral hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
2. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-75.
3. Katz AM. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation 1986;73:III-88.
4. Uretsky BF, Lawless CE, Verbalis J, Valdes AM, Kolesar JA, Reddy PS. Combined therapy with dobutamine and amrinone in severe heart failure. Chest 1987;92:657-62.
5. Armah BI, Hofferber E, Jacobitz P. Positive inotropic and vasodilatory actions of saterinone in vivo. Arzneimittelforschung 1988;38:1303-9.
6. Armah BI, Hofferber E, Stenzel W. Pharmacological properties of the positive inotropic and alpha 1-adrenoceptor blocking agent saterinone. Arzneimittelforschung 1988;38:1287-92.
7. 1-antagonist saterinone (INN) in healthy volunteers [Abstract]. Naunyn Schmiedebergs Arch Pharmacol 1988;338(suppl):R78.
8. Iven H, Djonlagic H. Pharmacokinetics and pharmacodynamics of saterinone in 12 healthy volunteers after i.v. infusion, and bioavailability from tablets [Abstract]. Naunyn Schmiedebergs Arch Pharmacol 1988;338(suppl):R77.
9. Pieske B, Bohm M, Erdmann E. Effect of saterinone on force of contraction and phosphodiesterase activity in isolated human myocardium [Abstract]. Naunyn Schmiedebergs Arch Pharmacol 1988;338(suppl):R46.
10. Baumann G, Kieback A, Eichner E, Iven H, Stolzenburg K. Pharmacokinetics and pharmacodynamics of saterinone i.v. in patients with severe chronic heart failure [Abstract]. Eur Heart J 1992;13(suppl):168.
11. Swan HJ, Ganz W, Forrester J, Marcus H, Diamond G, Chonette D. Catheterization of the heart in man with use of a flow-directed balloon-tipped catheter. N Engl J Med 1970;283:447-51.
12. Morganroth J, Borland M, Chao G. Application of a frequency definition of ventricular proarrhythmia. Am J Cardiol 1987;59:97-9.
13. Brouwer J, van Veldhuisen DJ, Man in't Veld AJ, et al. Heart rate variability in patients with mild to moderate heart failure: effects of neurohumoral modulation by digoxin and ibopamine. J Am Coll Cardiol 1995;26:983-90.
14. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996;5:1043-65.
15. Binkley PF, Nunziata E, Cody RJ. Influence of flosequinan on autonomic tone in congestive heart failure: implications for the mechanism of the positive chronotropic effect and survival influence of long-term vasodilator administration. Am Heart J 1994;128: 1147-56.
16. Szabó BM, van Veldhuisen DJ, Brouwer J, Haaksma J, Lie KI. Relation between severity of disease and impairment of heart rate variability parameters in patients with chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:713-6.
17. Binkley PF, Haas GJ, Starling RC, Nunziata E, Hatton PA, Leier CV. Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. J Am Coll Cardiol 1993;21:655-61.
18. Oosterziel KJ, Dietz R, Schmid W, Mikulaschek K, Manthey J, Kubler W. ACE inhibition improves vagal reactivity in patients with heart failure. Am Heart J 1990;120:1120-9.
19. Tuininga YS, van Veldhuisen DJ, Crijns HJGM, et al. Exploratory study of the effects of single doses of isomazole on hemodynamics and heart rate variability parameters in chronic heart failure. J Cardiovasc Pharmacol 1995;25:81-6.
20. Brouwer J, van Veldhuisen DJ, Man in't Veld AJ, et al. Prognostic value of heart rate variability during long-term follow-up in patients with mild to moderate heart failure. The Dutch ibopamine multicenter trial study. J Am Coll Cardiol 1996;28:1183-9.